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ABSTRACT
Background  In the IMAGE study, rituximab plus 
methotrexate (MTX) inhibited joint damage and improved 
clinical outcomes at 1 year in MTX-naïve patients with 
early active rheumatoid arthritis.
Objective  The aim of this study was to assess joint 
damage progression and clinical outcomes over 2 years.
Methods  Patients (n=755) were randomised to receive 
rituximab 2×500 mg+MTX, 2×1000 mg+MTX or 
placebo+MTX. The placebo-controlled period continued 
to week 104. Two-year end points were deﬁ  ned as 
secondary or exploratory and included change in total 
Genant-modiﬁ  ed Sharp score (mTSS), total erosion score 
and joint space narrowing score from baseline to week 
104. Clinical efﬁ  cacy and physical function end points 
were also assessed.
Results  At 2 years, rituximab 2×1000 mg+MTX 
maintained inhibition of progressive joint damage versus 
MTX alone (mTSS change 0.41 vs 1.95; p<0.0001 
(79% inhibition)), and a higher proportion of patients 
receiving rituximab 2×1000 mg+MTX had no 
radiographic progression over 2 years compared with 
those receiving MTX alone (57% vs 37%; p<0.0001). 
Contrary to 1-year results, exploratory analysis of 
rituximab 2×500 mg+MTX at 2 years showed that 
progressive joint damage was slowed by ~61% 
versus placebo+MTX (mTSS, exploratory p=0.0041). 
Improvements in clinical signs and symptoms and 
physical function seen after 1 year in rituximab-treated 
patients versus those receiving placebo were maintained 
at year 2. Safety proﬁ  les were similar between groups.
Conclusions  Treatment with rituximab 
2×1000 mg+MTX was associated with sustained 
improvements in radiographic, clinical and functional 
outcomes over 2 years. 
Clinical trials.gov identiﬁ  er NCT00299104.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inﬂ  amma-
tory disease in which joint damage and physical dis-
ability adversely affect quality of life and increase 
morbidity and premature mortality.1 2 Recent rec-
ommendations suggest that early treatment should 
be targeted towards the goal of clinical remission 
or low disease activity (LDA) and that this can lead 
to better structural and functional outcomes for 
patients. Furthermore, remission or LDA should be 
maintained throughout the course of the disease.3 4 
In addition to clinical targets, maintaining inhibi-
tion of joint damage is important for the patient, 
given the association between structural damage 
and long-term loss of function.5
B cell depletion with rituximab 2×1000 mg is an 
established and effective treatment for RA. In com-
bination with methotrexate (MTX), rituximab has 
been shown to signiﬁ  cantly reduce clinical signs 
and symptoms of RA in patients with an inadequate 
response (IR) to either conventional disease-mod-
ifying antirheumatic drugs or tumour necrosis fac-
tor (TNF) inhibitors6–9 and to inhibit radiographic 
progression in TNF-IR patients.9–11 In the IMAGE 
study—a randomised placebo-controlled trial of 
rituximab plus MTX in MTX-naïve patients with 
early active RA—rituximab 2×1000  mg+MTX 
signiﬁ   cantly inhibited progression of joint dam-
age and improved clinical outcomes and physi-
cal function compared with MTX alone after 
1 year.12 13 Here, we present clinical and radiographic 
outcomes from the 2-year analysis of this study.
METHODS
Full eligibility criteria have been previously report-
ed.12 In brief, patients were required to have a dis-
ease duration of ≥8 weeks but ≤4 years, no prior 
MTX treatment and active disease (swollen joint 
count (66 joints) and tender joint count (68 joints) 
both ≥8 at screening and baseline, and Creactive 
protein level ≥1.0 mg/dl). Patients seronegative 
for rheumatoid factor (RF) were only eligible if 
they had radiographic evidence of erosive dam-
age attributable to RA. This study was conducted 
in accordance with the Declaration of Helsinki and 
was approved by the institutional review board or 
the ethics committee at each study site. All patients 
gave written informed consent.
In October 2009, following a spontaneous 
report outside of clinical trials of a case of progres-
sive multifocal leucoencephalopathy (PML) in a 
rituximab-treated patient not previously treated 
with biologics, rituximab treatment was discon-
tinued in the IMAGE trial and patients were sub-
jected instead to safety follow-up. By this time, all 
patients had completed their 104-week follow-up 
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should be interpreted with caution. Exploratory p-values are 
denoted by ‘ex-p’.
Changes in radiographic scores were assessed with pairwise 
comparisons using a non-parametric test (Van Elteren) adjusted 
for baseline stratiﬁ  cation factors (RF and region). Missing val-
ues were imputed by linear extrapolation. Percentage of inhibi-
tion of radiographic progression was calculated as (mean mTSS 
change in placebo group−mean mTSS change in a rituximab 
group)×100/(mean mTSS change in placebo group). Differences 
in the proportions of patients without radiographic progression 
were assessed using the Cochran–Mantel–Haenszel test, adjust-
ing for baseline stratiﬁ  cation factors. Patients were deemed to 
have progressed if their progression status could not be deter-
mined. Clinical signs and symptoms and physical efﬁ  cacy dif-
ferences were assessed using the Cochran–Mantel–Haenszel 
test and analysis of variance for categorical and continuous end 
points, respectively, adjusting for baseline stratiﬁ  cation factors. 
Endpoint baseline values were included in analysis-of-variance 
models, if applicable. Non-responder imputations were used for 
categorical end points, and last observation carried forward was 
used for continuous end points.
RESULTS
A total of 755 patients were randomised, with 748 included 
in the intention-to-treat and safety population and 716 in the 
modiﬁ   ed intention-to-treat population analysed for radio-
graphic outcomes. Overall, 606 patients (80%) completed week 
104; lack of efﬁ  cacy and refusal of treatment were the most 
common reasons for withdrawal, with 4%, 3% and 5% of 
patients in the rituximab 2×500 mg+MTX, 2×1000 mg+MTX 
and placebo+MTX groups, respectively, withdrawing due to 
safety reasons. The proportion of randomised patients complet-
ing week 104 was higher in the rituximab 2×500 mg+MTX and 
2×1000 mg+MTX groups compared with the placebo+MTX 
group (85% and 85% vs 71%, respectively). At 2 years, 67–68% 
of patients had received a third course of treatment, with some 
patients receiving up to ﬁ  ve courses. The number of courses 
received was balanced between the placebo and rituximab treat-
ment groups; overall, 249, 250 and 249 patients in the rituximab 
2×500 mg+MTX, 2×1000 mg+MTX and placebo+MTX groups, 
respectively, received ≥1 course; 215, 219 and 212 received ≥2 
courses; 169, 172 and 169 received ≥3 courses; 106, 107 and 
122 received ≥4 courses; and 24, 26 and 31 received ≥5 courses. 
Baseline characteristics were similar across all treatment groups 
and have been reported previously.12 As at 1 year, MTX doses 
were similar across groups at 2 years.
Radiographic end points
At week 104, rituximab 2×1000 mg+MTX continued to inhibit 
progressive joint damage (PJD) in patients. The change in mTSS 
from baseline was 0.41 for patients treated with rituximab 
2×1000 mg+MTX compared with 1.95 in the placebo+MTX 
group (p<0.0001), equating to 79% inhibition in mTSS (ﬁ  gure 1). 
Change from baseline in total erosion score also continued 
to be signiﬁ   cantly lower with rituximab 2×1000 mg+MTX 
versus placebo+MTX at this time point (mean change 0.23 
vs 1.32; p<0.0001) (ﬁ   gure 1). Furthermore, a positive effect 
on joint space narrowing scores was observed with ritux-
imab 2×1000  mg+MTX versus placebo+MTX (0.18 vs 0.63; 
  ex-p=0.0183), an effect that was not seen at week 52 (ﬁ  gure 1). 
Also, contrary to the results observed at week 52, exploratory 
analysis showed that PJD was reduced in patients receiving 
rituximab 2×500 mg+MTX over the 2-year time period: change 
in mTSS was reduced by approximately 61% compared with 
and, consequently, the discontinuation does not impact the data 
presented here.
Patients were randomised (1:1:1) to receive rituximab 
2×500 mg+MTX, 2×1000 mg+MTX or placebo+MTX. Rituximab 
or placebo was administered by intravenous infusion on days 
1 and 15. Patients received intravenous methylprednisolone 
100 mg  premedication before all infusions. Oral MTX was 
commenced in all patients at 7.5 mg/week and escalated to 
20  mg/week by week 8, as tolerated. Repeat courses of ritux-
imab or placebo were permitted from week 24. To be eligible 
for re-treatment, patients had to have a Disease Activity Score 
in 28 joints (DAS28-erythrocyte sedimentation rate (ESR)) ≥2.6, 
with further re-treatment permitted 24 weeks after each course 
based on the same criteria. The placebo-controlled period con-
tinued to week 104. At week 52, the sponsor was unblinded to 
all treatment assignments for the purposes of data analysis, but 
investigators, sites, patients and radiographic readers remained 
blinded. Radiographs (hands, wrists and feet) were performed at 
screening and weeks 24, 52 and 104 and were read by two inde-
pendent expert radiologists using the Genant-modiﬁ  ed Sharp 
scoring system.14 15
The primary end point was the change in total Genant-
modiﬁ   ed Sharp score (mTSS) at week 52 from baseline.12 
At week 104, radiographic end points included the change in 
mTSS, total erosion score and joint space narrowing from base-
line to week 104. Proportions of patients with no progression 
in mTSS and erosion scores were also assessed. Clinical end 
points included the proportion of patients achieving American 
College of Rheumatology (ACR)20/50/70/90 criteria responses, 
European League Against Rheumatism (EULAR) responses and 
change in DAS28-ESR. ACR index of improvement in RA (ACRn) 
was calculated as described previously.16 Physical function was 
assessed using the Health Assessment Questionnaire-Disability 
Index (HAQ-DI). Radiographic outcomes and ACR50 responses 
were also analysed by serological status (RF and/or anticitrulli-
nated peptide antibody (ACPA) presence). Adverse events (AEs) 
were recorded throughout the study and graded according to 
the National Cancer Institute Common Terminology Criteria for 
Adverse Events (version 3).
STATISTICAL ANALYSIS
Radiographic end points were analysed using a modiﬁ  ed inten-
tion-to-treat population (all randomised and treated patients 
with a screening and at least one postbaseline radiographic 
evaluation). The intention-to-treat population (all patients ran-
domised and treated) was used for all other efﬁ  cacy and all 
safety end points.
Efﬁ  cacy end points were grouped and ranked according to 
three objectives (prevention of joint damage, improvement in 
clinical signs and symptoms and improvement in physical func-
tion). All clinical signs and symptoms end points at week 104 
were deﬁ  ned as exploratory in the protocol. Within the other 
two categories, all end points were secondary or exploratory at 
week 104, using a hierarchical approach to signiﬁ  cance testing to 
control for multiplicity. When an end point did not reach signiﬁ  -
cance at week 52, that end point and all end points lower in the 
hierarchy were treated as exploratory at week 104. When a sec-
ondary end point did not reach signiﬁ  cance at week 104, all end 
points lower in the hierarchy were treated as exploratory. The 
primary end point (change in mTSS vs placebo at week 52) was 
achieved for rituximab 2×1000 mg+MTX; however, the change 
in mTSS with rituximab 2×500 mg+MTX was not statistically 
signiﬁ  cant. Therefore, all p-values associated with radiographic 
outcomes at week 104 for this lower dose are exploratory and 
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(ACR70 maintained for at least six consecutive months) in each 
rituximab group compared with the placebo group (table 1).
Greater improvements in disease activity (as measured by mean 
change in EULAR response and DAS28-ESR) were also observed 
to week 104 in both rituximab+MTX groups compared with 
the placebo+MTX group (ﬁ  gure 3E,F). Almost two times more 
patients achieved a EULAR good response or DAS28-ESR clinical 
remission with rituximab+MTX compared with placebo+MTX 
(table 1). The proportions of patients with LDA and remission 
continued to increase over time in all treatment groups, but the 
increases were greatest in the rituximab+MTX groups.
Physical function
Improvements in physical function were also sustained through-
out the second year of treatment with both rituximab+MTX 
doses resulting in signiﬁ  cantly greater mean decreases in HAQ-DI 
score compared with placebo+MTX (p<0.0001 at week 104) 
(ﬁ  gure 4). At week 104, exploratory analysis indicated that the 
proportion of patients with at least a minimal clinically impor-
tant difference in HAQ-DI (decrease ≥0.22) was greater in the 
rituximab 2×1000 mg+MTX group than in the placebo+MTX 
group (table 1); proportions of patients achieving more marked 
improvements (ie, decreases of ≥0.3 or ≥0.5) were also greater in 
the rituximab 2×1000 mg+MTX group (data not shown). While 
the proportion of patients in the rituximab 2×500 mg+MTX 
group achieving the minimal clinically important difference in 
placebo+MTX (ex-p=0.0041), and erosive progression was 
slowed (mean change 0.50; ex-p=0.0019) (ﬁ  gure 1).
As observed at 1 year, a signiﬁ  cantly higher proportion of 
patients receiving rituximab 2×1000 mg+MTX showed no 
radiographic progression (deﬁ  ned as change in mTSS ≤0) over 
2 years compared with those receiving placebo+MTX (57% 
vs 37%; p<0.0001). In an exploratory analysis, a higher pro-
portion of patients in the rituximab 2×500 mg+MTX group 
also showed no progression compared with the placebo+MTX 
group (49% vs 37%; ex-p=0.0059). Across both rituximab 
groups, 82% of patients with no radiographic progression at 
week 52 maintained this status to week 104 compared with 
64% in the placebo group. A higher proportion of patients 
in the rituximab 2×500 mg and 2×1000 mg+MTX groups 
had no increase in erosion score at week 104 compared with 
the placebo+MTX group (53%, 59% and 38%, respectively; 
ex-p<0.001 and p<0.0001).
As previously reported, the majority of joint damage observed 
in rituximab-treated patients occurred between baseline and 24 
weeks.12 Thereafter, minimal further change occurred in both 
rituximab groups, whereas joint damage progression contin-
ued in a near-linear fashion in the placebo group (ﬁ  gure 2A). 
Annualised rates of progression of mTSS further demonstrated 
the markedly slowed disease progression from week 24 into the 
second year of treatment in both rituximab groups compared 
with the placebo group (ﬁ  gure 2B). From week 24 to week 104, 
rituximab 2×1000 mg+MTX demonstrated near-complete inhi-
bition (97%) of PJD compared with placebo+MTX (0.02 vs 0.72, 
respectively) and rituximab 2×500 mg+MTX induced 90% inhi-
bition of PJD versus placebo+MTX (0.07 vs 0.72, respectively).
This study was not powered to compare outcomes between 
rituximab doses; however, in an exploratory analysis, all radio-
graphic end points assessed from screening to week 104 for 
rituximab 2×1000 mg+MTX were numerically superior to ritux-
imab 2×500 mg+MTX (online supplementary table S1).
Clinical signs and symptoms
Exploratory analyses showed that the improved clinical out-
comes observed after 52 weeks were maintained at 104 weeks 
in both rituximab groups compared with the placebo group. 
ACR20/50/70/90 responses were achieved by higher propor-
tions of patients in each rituximab group compared with the 
placebo group over the 2 years (ﬁ  gure 3A–D). In addition, mean 
ACRn was higher at week 104 in the rituximab groups, and a 
larger proportion of patients achieved a major clinical response 
Figure 1  Change in radiographic end points at 2 years in the modiﬁ  ed 
intention-to-treat population. Linear extrapolation used for missing 
values. Adjusted p-values comparing rituximab+MTX groups with the 
placebo+MTX group; values in parentheses are unadjusted, exploratory 
p-values. mTSS, total Genant-modiﬁ  ed Sharp score; MTX, methotrexate; 
NS, non-signiﬁ  cant.
Figure 2  Rate of radiographic progression (change in mTSS) over 
2 years. (A) Mean change in mTSS. Linear extrapolation used for 
missing data. Error bars show ±1.96×standard error. (B) Annualised 
rate of progression of mTSS (all observed data). mTSS, total Genant-modiﬁ  ed 
Sharp score; MTX, methotrexate.
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Safety
Safety data over 104 weeks were consistent with those observed 
at 52 weeks with no new safety signals observed. The overall 
safety proﬁ  le of rituximab+MTX was similar to that observed in 
the placebo+MTX group (table 2).
Withdrawals due to AEs were low: 3% in both rituximab 
groups compared with 7% in the placebo group. There was no 
predominant AE that led to withdrawal. Six deaths occurred 
during the 104-week study: three in the placebo+MTX group 
(two due to pneumonia and one due to cerebral infarction), two 
in the rituximab 2×500 mg+MTX group (one due to pneumo-
nia; primary cause of death was unknown/unobtainable in the 
other—the patient had breathing difﬁ  culties and subsequently 
died in the hospital) and one in the rituximab 2×1000 mg+MTX 
group (due to duodenal ulcer). The incidence of all/serious AEs 
and rates of all/serious infections were similar across all treat-
ment groups (table 2). Proportions of patients experiencing 
HAQ-DI was numerically higher than in the placebo group, this 
did not reach statistical signiﬁ  cance.
Efﬁ  cacy in subgroups
Subgroup analysis was performed on data from patients sero-
positive or seronegative for RF and/or ACPA. At week 104, RF 
and/or ACPA seropositive patients treated with rituximab+MTX 
had a greater probability of having no radiographic progres-
sion, and a greater proportion achieved an ACR50 response, 
compared with patients receiving MTX alone. In seronegative 
patients, rituximab treatment had a less pronounced effect on 
radiographic responses and no effect on clinical responses. 
Comparisons between treatment groups should be interpreted 
with caution due to small numbers of seronegative patients 
and overlapping CI. Results are presented in online supplemen-
tary table S2.
Figure 3  Efﬁ  cacy over 2 years. (A) ACR20, (B) ACR50, (C) ACR70 and (D) ACR90 responses. LOCF used for tender and swollen joint counts, HAQ 
score, CRP, ESR and VAS assessments. ACRn was set to ‘non-responder’ when the score was missing. Patients were classiﬁ  ed as non-responders 
from the point of withdrawal or rescue use. (E) EULAR good response. LOCF used for tender and swollen joint counts, ESR and patient’s Global 
Assessment of Disease Activity VAS. EULAR response was set to ‘non-responder’ when the DAS28 score was missing. Patients were classiﬁ  ed 
as non-responders from the point of withdrawal or rescue use. (F) Mean change in DAS28. LOCF used for tender and swollen joint counts, ESR and 
patient’s Global Assessment of Disease Activity VAS. Error bars show ±1.96×standard error. ACR, American College of Rheumatology; CRP, C 
reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; 
HAQ, Health Assessment Questionnaire; LOCF, last observation carried forward; MTX, methotrexate; VAS, visual analogue scale.
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The proportion of patients showing no progression of joint 
damage after 2 years was signiﬁ  cantly higher in the rituximab 
dose groups compared with the placebo+MTX group. The ﬁ  g-
ure of 57% observed for the 2×1000 mg dose was almost identi-
cal (56.8%) to that seen at 2 years in a similar population treated 
with abatacept+MTX.17 The majority of joint damage progres-
sion in the current study was observed within the ﬁ  rst 6 months, 
with further damage almost entirely prevented thereafter; the 
reasons for this are unknown.
Over 2 years, both doses of rituximab continued to demon-
strate signiﬁ  cant improvements over placebo in relieving the 
signs and symptoms of RA, as exempliﬁ  ed by signiﬁ  cantly higher 
proportions of patients achieving ‘high-hurdle’ end points, such 
as ACR70 and ACR90, major clinical response, EULAR good 
response and DAS28 remission. In addition, improvements in 
physical function were maintained, with signiﬁ  cantly greater 
mean changes in HAQ-DI observed in both rituximab groups 
than in the placebo group throughout the observation period.
This study was not powered to compare rituximab doses, 
but exploratory results generally show that numerically greater 
responses for radiographic outcomes were achieved with the 
higher dose, while clinical outcome responses were generally 
numerically similar for both doses. In addition, the disconnect 
between radiographic and clinical responses with rituximab 
2×500 mg+MTX previously observed at 1 year was reduced 
at 2 years—an effect attributed to a slower onset of radiographic 
inhibition during the initial 6 months of treatment with the 
500-mg dose. A recent consensus statement18 discussed the opti-
mal dose of rituximab in patients with RA. The authors proposed 
that the 500-mg dose may provide equivalent clinical and radio-
graphic beneﬁ  ts to 1000 mg; however, the 500-mg dose is not 
approved and has not been studied in the licensed TNF-IR patient 
population. Consequently, further analysis would be required to 
conﬁ  rm any equivalence of doses. In the present study, while both 
rituximab doses provided beneﬁ  t in improving clinical signs and 
symptoms, data suggest that the higher dose slows PJD sooner, an 
observation that is relevant to an early population with RA (data 
presented in online supplementary table S1).
As at 1 year, and consistent with observations made in other 
patient populations,19–21 patients in the small subgroup who were 
seronegative for both RF and ACPA showed limited evidence of 
radiographic or clinical improvement with rituximab+MTX or 
at least one AE by treatment course were also comparable 
across all treatment groups (table 2). Infusion-related reactions 
remained the most common AE and were more frequent with 
the ﬁ  rst infusion of the ﬁ  rst course, declining thereafter. Serious 
infections were reported slightly more frequently in the placebo 
group (8%) than in either rituximab group (5% both groups). 
Three serious opportunistic infections occurred before week 
52 (one case of Pneumocystis jiroveci pneumonia and one case of 
Candida albicans in the rituximab 2×500 mg+MTX group; one case 
of pneumonia due to Pseudomonas aeruginosa/Pneumocystis carinii 
in the placebo+MTX group). No further serious opportunistic 
infections were reported between week 52 and week 104.
DISCUSSION
Treatment with rituximab 2×1000 mg in combination with 
MTX has previously been shown to result in signiﬁ  cant inhi-
bition of PJD over 1 year in MTX-naïve patients with early, 
active RA.12 The current analysis reports that these effects, 
including signiﬁ   cant reductions in mTSS and erosion score, 
are maintained over 2 years of treatment with rituximab 
2×1000 mg+MTX. Exploratory analysis also suggested that 
rituximab 2×500 mg+MTX slowed joint damage over 2 years.
Figure 4  Mean change in HAQ-DI over 2 years. LOCF was used for 
missing data. Error bars show ±1.96×standard error. HAQ-DI, Health 
Assessment Questionnaire-Disability Index; LOCF, last observation 
carried forward; MTX, methotrexate.
Table 1  Summary of clinical and physical function efﬁ  cacy outcomes over 104 weeks (intention-to-treat 
population)
Outcome
Placebo+MTX 
(n=249)
Rituximab 2×500 mg+MTX 
(n=249)
Rituximab 2×1000 mg+MTX 
(n=250)
Disease activity
  Major clinical response† (%) 22 39** 40**
 Mean  ACRn‡ 30.7 55.4 58.5
  EULAR good response (%) 23 44** 48**
  DAS28 LDA (%) 25 45** 48**
  DAS28 remission (%) 13 34** 32**
Physical function
 HAQ-DI  decrease  ≥0.22 (%) 77 84 86*
*p<0.05, **p<0.0001 versus placebo+MTX. All p-values are exploratory/descriptive.
†Major clinical response=ACR70 ≥6 months.
‡Number of patients with non-missing ACRn assessments for all groups was 248.
Analysis-of-variance model adjusted for stratiﬁ  cation factors (RF status, region) (adjusted mean changes shown in the table); 
Cochran–Mantel–Haenszel test was used for categorical variables, non-responder imputation was used for ACR major clinical 
response and EULAR response variables and last observation carried forward was used for DAS28 LDA, DAS28 remission and HAQ-DI.
ACRn, American College of Rheumatology index of improvement in RA; DAS28, Disease Activity Score in 28 joints; EULAR, 
European League Against Rheumatism; HAQ-DI, Health Assessment Questionnaire-Disability Index; LDA, low disease activity; MTX, 
methotrexate; RF, rheumatoid factor.
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guidelines, patients often now receive their second and subse-
quent biological treatment much sooner after RA diagnosis.3 4 
Consequently, the positive results presented here for the IMAGE 
trial, in which patients were treated on average 1 year after RA 
disease onset, may be relevant to a TNF-IR patient who initiates 
treatment with rituximab.
In conclusion, this 2-year analysis of the IMAGE study dem-
onstrates that rituximab 2×1000 mg+MTX led to sustained and 
signiﬁ  cant inhibition of joint damage progression and signiﬁ  cant 
improvements in clinical signs and symptoms of RA and func-
tional ability compared with MTX alone in an early population 
of patients with RA.
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placebo+MTX treatment. Conversely, radiographic and clinical 
responses among patients seropositive for RF and/or ACPA were 
signiﬁ  cantly improved for rituximab compared with MTX alone.
The 2-year safety proﬁ  le is consistent with that observed at 1 
year12 and with previously reported data in TNF-IR patients7 9 
and pooled data from long-term rituximab studies.22 The inci-
dence of serious infections remained low and consistent with 
previously reported rates,22 and no further opportunistic infec-
tions were reported beyond those observed up to week 52. 
Infusion-related reactions remained the most common safety 
event overall; however, their incidence generally declined fol-
lowing the ﬁ  rst infusion of the ﬁ  rst course.
No cases of PML were reported in this trial, and the overall 
reporting incidence of PML in patients with RA receiving ritux-
imab is very rare (5 cases in 129,000 patients with RA).23 The 
IMAGE trial was conducted in MTX-naïve patients with early 
disease, and many alternative treatment options are available 
for these patients; therefore, following a spontaneous report 
of a case of PML in a rituximab-treated patient not previously 
exposed to biological treatment,24 the sponsors took the deci-
sion to discontinue dosing with rituximab in the IMAGE trial.
Rituximab 2×1000 mg is currently licensed in combina-
tion with MTX for patients with RA who have had an IR or 
intolerance to other disease-modifying antirheumatic drugs, 
including one or more TNF inhibitor treatments. Rituximab is 
not approved for use in the MTX-naïve population described 
here, but these data demonstrate the value of rituximab+MTX 
in preventing progression of structural joint damage, a key goal 
of treatment. Furthermore, under recent recommendations and 
Table 2  Summary of safety proﬁ  le over 104 weeks (safety population)
  Placebo+MTX 
(n=249)
Rituximab 2×500 
mg+MTX (n=249)
Rituximab 2×1000 
mg+MTX (n=250)
Patient-years of observation 422.11 457.92 462.09
AE incidence, n (%)
Any AE 215 (86) 206 (83) 217 (87)
First course* 183 (73) 167 (67) 188 (75)
Second course* 135 (64) 128 (60) 140 (64)
Third course* 107 (63) 96 (57) 111 (65)
Fourth course*   52 (43) 55 (52) 55 (51)
Fifth course*     5 (16) 7 (29) 8 (31)
Any serious AE (all courses)   42 (17) 37 (15) 33 (13)
AE leading to withdrawal (all courses)   17 (7) 8 (3) 7 (3)
All deaths†   3  (1)   2  (<1) 1  (<1)
Infusion-related reaction, n (%)
First course*   31 (12)   35 (14) 46 (18)
Second course*   21‡(10) 20 (9) 21 (10)
Third course*   10 (6) 11 (7) 12 (7)
Fourth course* 10 (8) 10 (9) 8 (7)
Fifth course* 2 (6) 1 (4) 3 (12)
Infection, n (%)
Any 146 (59) 162 (65) 160 (64)
Serious§ 19 (8) 13 (5) 12 (5)
Malignancy, n (%)
Any 7 (3) 6 (2) 3 (1)
Serious 6 (2) 5 (2) 2 (<1)
AE rates per 100 patient-years (95% CI)
Overall infection rate   99.50 (90.42 to 109.49)   92.37 (83.98 to 101.61)   109.50 (100.36 to 119.47)
Serious infection§ rate     4.97 (3.24 to 7.63)     4.15 (2.65 to 6.50)     3.25 (1.96 to 5.38)
*Percentage of incidence based on number receiving each treatment course (as described in the Results section).
†Includes patients who died during the safety follow-up period.
‡One patient was randomised to placebo but received rituximab at the second course during which the patient experienced a mild 
infusion-related reaction. The patient did not experience any serious AEs during the study; this patient’s data are summarised under 
placebo.
§Reported as serious and/or treated with intravenous antibiotics.
AE, adverse event; MTX, methotrexate.
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